Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 1256Neoplasms 1074Carcinoma, Non-Small-Cell Lung 874Prostatic Neoplasms 714Lung Neoplasms 596Colorectal Neoplasms 590Neoplasm Metastasis 452Multiple Myeloma 432Leukemia, Myeloid, Acute 423Pancreatic Neoplasms 370Ovarian Neoplasms 367Melanoma 324Carcinoma, Hepatocellular 299Squamous Cell Carcinoma of Head and Neck 276Brain Neoplasms 275Recurrence 273Stomach Neoplasms 245Head and Neck Neoplasms 241Glioblastoma 239Carcinoma, Renal Cell 227Lymphoma 226Triple Negative Breast Neoplasms 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Hematologic Neoplasms 212Urinary Bladder Neoplasms 211Uterine Cervical Neoplasms 200Endometrial Neoplasms 199Sarcoma 195Glioma 194Lymphoma, Non-Hodgkin 188

Interventions

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ventricular Dysfunction, Left × 90 days × Clear all
NCT07572175 2026-05-07

SPARTACUS

Icahn School of Medicine at Mount Sinai

Phase 2 Not yet recruiting
60 enrolled
Lymphoid

Lymphoma, Ventricular Dysfunction, Left, Cardiotoxicity

NCT07515859 2026-04-13

Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography

Yonsei University

Completed
31,486 enrolled

Heart Failure, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡